X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1400) 1400
Publication (45) 45
Book Review (22) 22
Book Chapter (3) 3
Magazine Article (3) 3
Book / eBook (1) 1
Newsletter (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1234) 1234
male (784) 784
alprostadil - therapeutic use (594) 594
female (540) 540
alprostadil - administration & dosage (491) 491
alprostadil - adverse effects (485) 485
middle aged (470) 470
adult (453) 453
alprostadil - analogs & derivatives (373) 373
aged (336) 336
alprostadil (271) 271
index medicus (266) 266
erectile dysfunction - drug therapy (237) 237
vasodilator agents - administration & dosage (211) 211
treatment outcome (207) 207
urology & nephrology (207) 207
alprostadil - pharmacology (182) 182
impotence (181) 181
vasodilator agents - therapeutic use (178) 178
erectile dysfunction (169) 169
animals (157) 157
misoprostol (155) 155
double-blind method (141) 141
pregnancy (140) 140
vasodilator agents - adverse effects (139) 139
erectile dysfunction - etiology (124) 124
time factors (114) 114
dose-response relationship, drug (110) 110
infant, newborn (109) 109
sildenafil citrate (109) 109
injections (107) 107
prospective studies (107) 107
pharmacology & pharmacy (102) 102
men (95) 95
care and treatment (92) 92
infusions, intravenous (92) 92
medicine, general & internal (92) 92
clinical trials as topic (90) 90
surgery (89) 89
drug therapy, combination (88) 88
adolescent (87) 87
double-blind (86) 86
penile erection - drug effects (84) 84
therapy (83) 83
efficacy (81) 81
retrospective studies (80) 80
anti-ulcer agents - therapeutic use (78) 78
risk factors (78) 78
aged, 80 and over (77) 77
prostaglandin e1 (76) 76
lubiprostone (75) 75
prostaglandin e (73) 73
prostaglandins e (73) 73
abortifacient agents, nonsteroidal - adverse effects (72) 72
prostaglandin-e1 (72) 72
medicine & public health (70) 70
prostatectomy - adverse effects (70) 70
penile erection (69) 69
purines (68) 68
piperazines - therapeutic use (67) 67
sildenafil (67) 67
prostaglandins (66) 66
sulfones (65) 65
rats (64) 64
phosphodiesterase inhibitors - therapeutic use (63) 63
obstetrics & gynecology (62) 62
safety (62) 62
penis (60) 60
anti-inflammatory agents, non-steroidal - adverse effects (59) 59
constipation - drug therapy (59) 59
papaverine (59) 59
follow-up studies (56) 56
administration, oral (55) 55
drug therapy (55) 55
randomized controlled trials as topic (54) 54
abortifacient agents, nonsteroidal - administration & dosage (53) 53
patient satisfaction (51) 51
transurethral alprostadil (51) 51
quality-of-life (50) 50
cardiac & cardiovascular systems (49) 49
erectile dysfunction - therapy (49) 49
abortion, induced (46) 46
drug administration schedule (46) 46
papaverine - administration & dosage (45) 45
heart defects, congenital - drug therapy (44) 44
analysis (43) 43
gastroenterology & hepatology (42) 42
erectile dysfunction - physiopathology (41) 41
pediatrics (41) 41
pregnancy trimester, second (41) 41
prostaglandin e-1 (41) 41
dysfunction (40) 40
phentolamine - administration & dosage (40) 40
random allocation (40) 40
administration, intravaginal (39) 39
constipation (39) 39
intracavernous injection (39) 39
abortion, induced - methods (38) 38
blood pressure - drug effects (38) 38
health aspects (38) 38
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1268) 1268
German (58) 58
Japanese (44) 44
French (21) 21
Chinese (15) 15
Spanish (12) 12
Danish (8) 8
Italian (7) 7
Russian (6) 6
Hungarian (2) 2
Portuguese (2) 2
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
Norwegian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Sexual Medicine, ISSN 1743-6095, 01/2013, Volume 10, Issue 1, pp. 130 - 171
Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male... 
Erectile Dysfunction | Phosphodiesterase Inhibitors | Vacuum Device Therapy | Oral Drug Treatment | Combination Therapies | Transurethral Alprostadil Therapy | Intracavernous Self-Injection Therapy | Intracavernous Self‐Injection Therapy | INTRACAVERNOUS ALPROSTADIL ALFADEX | BENIGN PROSTATIC HYPERPLASIA | PHOSPHODIESTERASE TYPE-5 INHIBITOR | URINARY-TRACT SYMPTOMS | ONCE-A-DAY | LONG-TERM SAFETY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | VACUUM CONSTRICTION DEVICE | SELF-INJECTION THERAPY | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Male | Alprostadil - therapeutic use | Erectile Dysfunction - therapy | Aged, 80 and over | Imidazoles - therapeutic use | Imidazoles - adverse effects | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Alprostadil - adverse effects | Yohimbine - adverse effects | Piperazines - therapeutic use | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Piperazines - adverse effects | Sulfonamides - pharmacokinetics | Yohimbine - therapeutic use | Tadalafil | Vardenafil Dihydrochloride | Pyrimidines - pharmacokinetics | Hypogonadism - therapy | Triazines - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Triazines - pharmacokinetics | Piperazines - administration & dosage | Sulfones - therapeutic use | Age Factors | Triazines - therapeutic use | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Alprostadil - administration & dosage | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | Adult | Phosphodiesterase 5 Inhibitors - therapeutic use | Piperazines - pharmacokinetics | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Pyrimidines - administration & dosage | Erectile Dysfunction - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Triazines - administration & dosage | Hypogonadism - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Carbolines - pharmacokinetics | Hypertension | Care and treatment | Conservatism | Online health care information services | Impotence | Prosthesis | Chronic diseases | Risk factors | Testosterone | Implants, Artificial | Prostaglandins E | Diabetes | Vasoactive intestinal peptides | Special education
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1465-1858, 02/2018, Volume 2018, Issue 2, p. CD011417
Prostaglandin E1 (PGE1) is used to keep the ductus arteriosus patent and can be life-saving in neonates with ductal-dependent cardiac lesions. PGE1 is used to... 
Alprostadil - therapeutic use | Vasodilator Agents - therapeutic use | Ductus Arteriosus, Patent - drug therapy | Humans | Alprostadil - adverse effects | Vasodilator Agents - adverse effects | Infant, Newborn
Journal Article
Journal Article
Journal Article
Journal Article